The renewal of the US priority review voucher (PRV) is vital for the biotech sector, SynaptixBio CEO Dan Williams has said.  The US Food and Drug Administration (FDA)’s PRV scheme, designed to incentivise rare disease drug development, was reauthorised by the US House of Representatives on December 1.   Williams, whose company is developing a drug to treat […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!